INVESTORS & PARTNERS

logo Vaxdyn blanco-verde

Backing the development of vaccines against antibiotic-resistant infections

Vaxdyn’s programs are supported by a combination of equity investors, non-dilutive funders and research collaborators committed to addressing antimicrobial resistance.


INVESTORS

In July 2026, Vaxdyn closed a €11 million Series A financing led by Biovance Capital, with participation from the EIC Fund and Impacto Andalucía, alongside the company’s existing shareholders. The round funds clinical validation of Vaxdyn’s bacterial vaccine platform through a Phase 1 trial of K-Vax, the company’s lead candidate for the prevention of disease caused by Klebsiella pneumoniae and supports the advancement of preclinical programs targeting Pseudomonas aeruginosa and Escherichia coli.

Biovance Capital is Portugal’s leading life sciences investor. The company manages Biovance Capital Fund I, a € 60 million venture capital fund backed by the European Investment Fund and the European Commission through the Portugal Tech and InvestEU programmes, the largest Portuguese pharmaceutical company BIAL, the national promotional bank Banco Português de Fomento, and private investors such as Caixa Capital, Ageas Pensões, and Fundo de Pensões EDP, in addition to other private investors from the USA and Europe.

Impacto Andalucía Innovación y Desarrollo SICC, S.A.U. (https://arcanofdiandalucia.com/) is one of the funds selected by the European Investment Bank to deploy the RDI and Digital Andalucia financial instrument, financed by the ERDF programme and the Regional Government of Andalusia through the Regional Ministry of Economy, Finance and European Funds. Arcano Partners founded in 2003, is an independent global firm with more than 20 years of experience in financial advisory and international asset management.

The European Investment Bank Group (EIB Group) is the financial arm of the European Union, owned by its 27 Member States, and is one of the world’s largest multilateral development banks. With the support of the 27 EU governments, the European Investment Fund (EIF) has joined forces with institutional investors in a pan-European alliance to mobilise up to €80 billion for investment in innovative companies scaling up to become global leaders.


Powered by CARB-X

Vaxdyn’s research is supported by CARB-X. Funding for CARB-X has been provided by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) and by awards from Wellcome, the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, The Public Health Agency of Canada, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The content of this site is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X funders.

CARB X European PD Spotligh

CARB X European PD Spotligh


Since 2019, Vaxdyn has secured approximately €13 million in non-dilutive funding from national and international programs supporting AMR innovation, including CARB-X, the EIC Accelerator, Spain AEI, CDTI and the EUROSTARS program of the EU.


Before the Series A, the seed capital was provided by private investors including The Mind the Gap investment vehicle led by The Botín Foundation, who joined Vaxdyn’s founders in 2020 and 2021.


PARTNERS

For vaccine development, Vaxdyn is working with its key partners:

  • National Center for Microbiology, Carlos III Health Institute (CNM-ISCIII) — Madrid, Spain.
  • LEITAT Technological Center — Barcelona, Spain.
  • López-Neyra Institute of Parasitology and Biomedicine, Spanish National Research Council (IPBLN-CSIC) — Granada, Spain.
  • Institute of Research and Innovation in Biomedical Sciences of Cádiz (INiBICA) — Cádiz, Spain.
  • Biomedical Research Institute of A Coruña (INIBIC) — A Coruña, Spain.
  • University of Córdoba (UCO) — Córdoba, Spain.
  • Laboratorios Reig Jofre — Barcelona, Spain.


CONTACT

Vaxdyn

Supported by

CONTACT US


Vaxdyn logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.